Nautilus Biotechnology (NAUT) Total Current Liabilities (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Total Current Liabilities of $8.6 million for Q2 2026, up 3.55% sequentially from $8.3 million in Q1 2026, and up 6.17% YoY from $8.1 million in Q2 2025.
Nautilus Biotechnology (NAUT) Total Current Liabilities (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Total Current Liabilities for 7 years, with the latest figure at $8.6 million in Q2 2026.
- Quarterly Total Current Liabilities rose 6.17% year-over-year to $8.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $8.6 million (up 6.17% YoY) and the FY2025 annual result came in at $8.0 million, up 4.19% from the prior year.
- Total Current Liabilities improved to $8.6 million in Q2 2026 per NAUT's latest filing, from $8.3 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $9.2 million in Q1 2024 and troughed at $6.1 million in Q2 2022.
- A 5-year average of $8.0 million and a median of $8.1 million in 2025 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Current Liabilities jumped 256.02% in 2022, then declined 16.33% in 2024.
- Over 5 years, Total Current Liabilities stood at $6.8 million in 2022, then surged by 34.32% to $9.1 million in 2023, then dropped by 16.33% to $7.6 million in 2024, then rose by 4.19% to $8.0 million in 2025, then climbed by 8.64% to $8.6 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $8.6 million, $8.3 million, and $8.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - | 630.93 Mn |
| 10 | Nautilus Biotechnology | 119.13 Mn | 119.13 Mn | 175,000.00 | 8.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.64 Mn |
| Mar 31, 2026 | 8.34 Mn |
| Dec 31, 2025 | 7.95 Mn |
| Sep 30, 2025 | 8.98 Mn |
| Jun 30, 2025 | 8.14 Mn |
| Mar 31, 2025 | 8.16 Mn |
| Dec 31, 2024 | 7.63 Mn |
| Sep 30, 2024 | 8.66 Mn |
| Jun 30, 2024 | 8.68 Mn |
| Mar 31, 2024 | 9.21 Mn |
| Dec 31, 2023 | 9.12 Mn |
| Sep 30, 2023 | 8.89 Mn |
| Jun 30, 2023 | 7.89 Mn |
| Mar 31, 2023 | 7.93 Mn |
| Dec 31, 2022 | 6.79 Mn |
| Sep 30, 2022 | 6.43 Mn |
| Jun 30, 2022 | 6.10 Mn |
| Mar 31, 2022 | 6.41 Mn |
| Dec 31, 2021 | 5.81 Mn |
| Sep 30, 2021 | 4.21 Mn |